1198615-70-1

Basic information

• Product Name: (3-ETHOXYCARBONYLMETHYLPHENYL)BORONIC ACID, PINACOL ESTER
• Synonyms: (3-ETHOXYCARBONYLMETHYLPHENYL)BORONIC ACID, PINACOL ESTER;ethyl 2-(3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate;Ethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
• CAS NO: 1198615-70-1
• Molecular Formula: C₁₆H₂₃BO₄
• Molecular Weight: 308.1777
• Mol File: 1198615-70-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 386.4±25.0 °C(Predicted)
• Appearance: /
• Density: 1.06±0.1 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• CAS DataBase Reference: (3-ETHOXYCARBONYLMETHYLPHENYL)BORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (3-ETHOXYCARBONYLMETHYLPHENYL)BORONIC ACID, PINACOL ESTER(1198615-70-1)
• EPA Substance Registry System: (3-ETHOXYCARBONYLMETHYLPHENYL)BORONIC ACID, PINACOL ESTER(1198615-70-1)

Safety Data

• Hazardous Substances Data: 1198615-70-1(Hazardous Substances Data)

Usage

Description

(3-Ethoxycarbonylmethyl)phenylboronic Acid, Pinacol Ester is a chemical compound with the molecular formula C11H15BO4. It is a derivative of boronic acid and is characterized by its ability to form stable covalent bonds with diols, making it a versatile reagent in various chemical and biological applications.

Uses

Used in Pharmaceutical Industry:
(3-Ethoxycarbonylmethyl)phenylboronic Acid, Pinacol Ester is used as a reagent for the identification of a novel class of autotaxin inhibitors through cross-screening. Autotaxin is an enzyme involved in various biological processes, and its inhibition has potential therapeutic applications in treating diseases such as cancer and fibrosis. The compound's ability to form stable bonds with diols allows for the selective identification and characterization of autotaxin inhibitors, contributing to the development of new therapeutic strategies.

Upstream product

• 14062-30-7 ethyl 2-(3-bromophenyl)acetate 
• 73183-34-3 bis(pinacol)diborane 
• 75-03-6 ethyl iodide 
• 1878-67-7 3-Bromophenylacetic acid 

Downstream Products

• 1616077-59-8 ethyl 2-(3-(1-methyl-1H-pyrazol-5-yl)phenyl)acetate 
• 1616075-20-7 N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-2-(3-(1-methyl-1H-pyrazol-5-yl)phenyl)acetamide 
• 1616077-60-1 2-(3-(1-methyl-1H-pyrazol-5-yl)phenyl)acetic acid 
• 1454928-12-1 ethyl 2-(4'-(((1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methoxy)methyl)-[1,1 '-biphenyl]-3-yl)acetate 
• 1290053-82-5 [3-(2-{4-[3-(aminomethyl)phenyl]piperidin-1-yl}-2-oxoethyl)phenyl]boronic acid 
• 1411772-67-2 ethyl {3-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]phenyl}acetate 
• 1379989-16-8 [3-(1H-pyrazol-4-yl)phenyl]acetic acid 
• 1411772-68-3 ethyl [3-(1H-pyrazol-4-yl)phenyl]acetate 
• 1185737-33-0 [2'-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-ylmethyl)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid 

Relevant articles and documents

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis

Biphenylacetic acid (5) was identified through a library screen as an inhibitor of the prostaglandin D2 receptor DP2 (CRTH2). Optimization for potency and pharmacokinetic properties led to a series of selective CRTH2 antagonists. Compounds demonstrated potency in a human DP2 binding assay and a human whole blood eosinophil shape change assay, as well as good oral bioavailability in rat and dog, and efficacy in a mouse model of allergic rhinitis following oral dosing.